Vertex Pharmaceuticals

YTD

ALL

Trade Vertex Pharmaceuticals 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About VRTX

Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis.

CEO

Reshma Kewalramani

CEOReshma Kewalramani

Employees

6,100

Employees6,100

Headquarters

Boston, Massachusetts

HeadquartersBoston, Massachusetts

Founded

1989

Founded1989

Employees

6,100

Employees6,100

VRTX Key Statistics

Market cap

129.15B

Market cap129.15B

Price-Earnings ratio

-228.42

Price-Earnings ratio-228.42

Dividend yield

—

Dividend yield—

Average volume

1.49M

Average volume1.49M

High today

—

High today—

Low today

—

Low today—

Open price

$493.66

Open price$493.66

Volume

0.00

Volume0.00

52 Week high

$519.88

52 Week high$519.88

52 Week low

$377.85

52 Week low$377.85

VRTX News

Benzinga 7d

Vertex Newly Approved Pain Treatment Lands Higher Cost Tier 3 Placement In UnitedHealth's Optum Rx Formularies

In January, the Food and Drug Administration (FDA) approved Vertex Pharmaceuticals Inc. VRTX Journavx, a non-opioid oral pain signal inhibitor for acute pain....

Simply Wall St 7d

Vertex Pharmaceuticals (NasdaqGS:VRTX) Gains UK Approval For New Cystic Fibrosis Treatment

On March 7, 2025, announced that its cystic fibrosis treatment, ALYFTREK®, had received regulatory approval from the UK's MHRA, a significant milestone in expan...

Analyst ratings

57%

of 35 ratings

Buy

57.1%

Hold

37.1%

Sell

5.7%